THE DEFINITIVE GUIDE TO DUP-697

These trials confirmed clinically important pharmacokinetic interactions [seven] characterised by a minimize in the clearance in the anticancer drug and as a result elevated exposure. The interpretation of subsequent stage II and III clinical trials was difficult because it was impossible to administer precisely the same dose of chemotherapy during